CR Bard, Inc. v. Wordtronics Corp.

561 A.2d 694, 235 N.J. Super. 168
CourtNew Jersey Superior Court Appellate Division
DecidedApril 28, 1989
StatusPublished
Cited by25 cases

This text of 561 A.2d 694 (CR Bard, Inc. v. Wordtronics Corp.) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CR Bard, Inc. v. Wordtronics Corp., 561 A.2d 694, 235 N.J. Super. 168 (N.J. Ct. App. 1989).

Opinion

235 N.J. Super. 168 (1989)
561 A.2d 694

C.R. BARD, INC., A CORPORATION OF THE STATE OF NEW JERSEY, PLAINTIFF,
v.
WORDTRONICS CORP., A CORPORATION OF THE STATE OF NEW YORK, AND WX COMMUNICATIONS, INC., A SUBSIDIARY CORPORATION, AND MEADOX MEDICALS, INC., A CORPORATION, DEFENDANTS.

Superior Court of New Jersey, Law Division (Civil) Union County.

April 28, 1989.

*170 Richard E. Brennan, for plaintiff (Shanley & Fisher, attorneys).

Thomas J. Goodwin, for defendant (Krugman, Chapnick & Grimshaw, attorneys).

MENZA, J.S.C.

This is defendant — Meadox's motion for summary judgment. The unique question presented is whether a true statement made in a letter to third persons by one competitor about another competitor's product can constitute a basis for liability, when the competitor disseminates the information through a marketing survey company employed for that specific purpose.

Plaintiff, C.R. Bard, and defendant, Meadox Medicals, are manufacturers of artificial vascular grafts, a medical device used by surgeons. (The device is also known as a vascular prosthesis). Defendant, Wordtronics Corporation, is a company engaged in the marketing of various products.

In February 1988, the Food and Drug Administration (FDA), adopted a regulation which required all manufacturers of vascular grafts to obtain from the FDA either premarketing approval (PMA), or an investigational device exemption (IDE), as prerequisites to the lawful marketing of their product.

Plaintiff, which had marketed vascular grafts for many years prior to the FDA regulation, failed to comply with the FDA *171 requirement, and continued to market its grafts without FDA approval.

Sometime after the adoption of the FDA regulations, defendant-Meadox employed defendant-Wordtronics to assist it in the marketing of its vascular grafts.

Thereafter, Wordtronics sent letters to a number of health care providers whose names had been furnished by Meadox, informing them of the fact that there was no currently marketed vascular graft which had FDA approval. The contents of this letter were prepared by Meadox. The letter stated:

On June 1, 1988, the Food and Drug Administration (FDA) stated that impregnated or coated vascular prosthesis will now be considered Class III medical devices. As such, manufacturers of these products must now submit an Investigational Device Exemption (IDE) for clinical evaluation and a Pre-marketing Approval Application (PMAA (sic)) for usage in general patient population.... To date, no currently marketed coated graft has yet been granted a PMAA (sic) by the FDA. However, one continues to be commercially marketed.

After receiving the letter, numerous medical-care providers either returned their store of vascular grafts to plaintiff or cancelled their existing orders.

Plaintiff claims that it has been damaged as a result of this letter, and has brought an action against defendants for the torts of interference with contractual relations, product disparagement and unfair competition. Plaintiff's position is succinctly set forth in its brief:

In a cunningly contrived masquerade conducted under the guise of an independent study by Wordtronics' nonexistent `Health Care Research Division,' defendants conducted a poison pen campaign against Bard's product in an underhanded and deceptive attempt `to get the market ready for (Meadox's) new competing graft.'
Defendant's actions are clearly in violation of the standards of fairness and commercial morality imposed by the law of this State.

Defendants respond that the contents of the letter were true and dealt with matters of public concern, and that therefore, plaintiff does not have a cause of action.

Interference with contracts is:

... imposed upon a defendant who intentionally and improperly interferes with the plaintiff's right to a contract with another person ... (or with) the *172 plaintiff's prospects of economic gain even where these prospects have not been reduced to a contract right. [Prosser & Keaton, Torts, (5 ed. 1984), § 129 at ___]

Product disparagement (injurious falsehood):

... consists of the publication of matter derogatory to the plaintiff's title to his property, or its quality, or to his business in general, or even to some element of his personal affairs, of a kind calculated to prevent others from dealing with him or otherwise to interfere with others to his disadvantage. [Id. at ___]

This cause of action is an off-shoot of the cause of action for unlawful interference. It requires the communication of the falsehood to third persons. See Dairy Stores v. Sentinel Pub. Co., 104 N.J. 125, 134 (1986).

There is no distinct cause of action for unfair competition. It is a general rubric which subsumes various other causes of action.

The Restatement, (Torts 2d, § 768 (1979) sets forth the parameters within which a competitor may compete:

Competition as Proper or Improper Interference
(1) One who intentionally causes a third person not to enter into a prospective contractual relation with another who is his competitor or not to continue an existing contract terminable at will does not interfere improperly with the other's relation if
(a) the relation concerns a matter involved in the competition between the actor and the other and
(b) the actor does not employ wrongful means and
(c) his action does not create or continue an unlawful restraint of trade and
(d) his purpose is at least in part to advance his interest in competing with the other. [Id at ___]

Subsections (a), (c) and (d) are satisfied in this case. Plaintiff and defendant-Meadox are competitors; the letter concerned a matter which was the subject of their competition; the letter was distributed for the purpose of advancing the interest of defendant-Meadox, and defendant's action neither created nor constituted an unlawful restraint of trade.[1]

*173 It is plaintiff's contention that the letter was untruthful and misleading, and that defendant-Meadox harbored bad motives in disseminating it. It also contends that defendant-Meadox used wrongful means in competing with plaintiff. Specifically, it maintains that defendant-Meadox utilized defendant-Wordtronics as a conduit in order to give third persons the impression that the information in the letter was the result of an independent marketing research survey, when, in fact, it was only one competitor speaking disparagingly about another competitor's product. Plaintiff contends that the means used by Meadox were, therefore, unlawful.

Defendant's motive is not relevant to the determination of this case. Its motive was to compete, i.e., to induce users of the vascular grafts to purchase the device from the Meadox Company, rather than from plaintiff. There is simply nothing wrong with that. A competitor has an absolute right to take away as much of the "other fellow's" business as he can lawfully. See Louis Kamm, Inc., v. Flink, 113 N.J.L. 582, 587 (E. & A. 1934) ("Everyone has a right to enjoy the fruits and advantages of his own enterprise, industry, skill and credit. He has no right to be protected against competition....").

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nostrame v. Santiago
61 A.3d 893 (Supreme Court of New Jersey, 2013)
Cargill Global Trading v. APPLIED DEVELOPMENT COMPANY
706 F. Supp. 2d 563 (D. New Jersey, 2010)
Johnson & Johnson v. Guidant Corp.
525 F. Supp. 2d 336 (S.D. New York, 2007)
Ary Jewelers, LLC. v. IBJTC Business Credit Corp.
414 F. Supp. 2d 90 (D. Massachusetts, 2006)
Safeway Ins. Co., Inc. v. Guerrero
106 P.3d 1020 (Arizona Supreme Court, 2005)
Trade 'N Post, L.L.C. v. World Duty Free Americas, Inc.
2001 ND 116 (North Dakota Supreme Court, 2001)
A.K. Stamping Co. v. Instrument Specialties Co.
106 F. Supp. 2d 627 (D. New Jersey, 2000)
Tiernan v. Charleston Area Medical Center, Inc.
506 S.E.2d 578 (West Virginia Supreme Court, 1998)
Beck v. Tribert
711 A.2d 951 (New Jersey Superior Court App Division, 1998)
East Penn Sanitation, Inc. v. Grinnell Haulers, Inc.
682 A.2d 1207 (New Jersey Superior Court App Division, 1996)
E Z Sockets, Inc. v. Brighton-Best Socket Screw Mfg. Inc.
704 A.2d 1364 (New Jersey Court of Chancery, 1996)
Ideal Dairy Farms, Inc. v. Farmland Dairy Farms, Inc.
659 A.2d 904 (New Jersey Superior Court App Division, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
561 A.2d 694, 235 N.J. Super. 168, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cr-bard-inc-v-wordtronics-corp-njsuperctappdiv-1989.